|
|
CSL Behring is committed to saving lives and improving
the quality of life for people with rare and serious
diseases worldwide. Our life-saving biotherapies are
used in the treatment of hemophilia, von Willebrand
disease, immune deficiencies and genetic emphysema.
4 March 2010Hizentra™ Receives U.S. FDA Approval
1 March 2010HAE Data Presented at AAAAI
1 March 201020% Subcutaneous Ig Data Presented at AAAAI
29 December 2009CSL Behring Awards 4th Round of LEAD Grants
9 November 2009CSL Behring Enhances Packaging for Humate-P
|